Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Tranzyme Pharma to Report First Quarter 2013 Financial Results



Tranzyme Pharma to Report First Quarter 2013 Financial Results

RESEARCH TRIANGLE PARK, N.C., May 2, 2013 (GLOBE NEWSWIRE) -- Tranzyme Pharma
(Nasdaq:TZYM), today announced that the Company will report first quarter 2013
financial results after the close of the market on Thursday, May 9, 2013.

About Tranzyme Pharma

Tranzyme Pharma is a biopharmaceutical company focused on discovering,
developing and commercializing novel, mechanism-based therapeutics. All of
Tranzyme's drug discovery activities are based on its proprietary small
molecule macrocyclic template chemistry (MATCH™) technology, which has also
been successfully used to generate drug candidates in partnership with other
pharmaceutical companies. MATCH enables the rapid construct of synthetic
libraries of drug-like, macrocyclic compounds in a predictable and efficient
manner. By leveraging MATCH, Tranzyme is committed to pursuing first-in-class
medicines to address areas of significant unmet medical need and continues to
pursue funded drug discovery partnerships. Additional information on Tranzyme
can be found at www.tranzyme.com.

CONTACT: Inquiries:
         Susan Sharpe
         Director, Corporate Communications
         (919) 328-1109
         ssharpe@tranzyme.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement